Coherus BioSciences, Inc. (CHRS)
收市後：
| 前收市價 | 2.1200 |
| 開市 | 2.1700 |
| 買盤 | 1.8800 x 800 |
| 賣出價 | 1.9100 x 500 |
| 今日波幅 | 1.8100 - 2.1800 |
| 52 週波幅 | 1.4300 - 5.6300 |
| 成交量 | |
| 平均成交量 | 2,270,504 |
| 市值 | 215.646M |
| Beta 值 (5 年，每月) | 0.56 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.5300 |
| 業績公佈日 | 2024年7月31日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 10.43 |
Insider MonkeyCoherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript May 10, 2024. CHRS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to Coherus […]
ZacksCoherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Insider Monkey
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript March 13, 2024 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.21. CHRS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]
